Dassault Systèmes agreed to acquire Arisglobal for up to $2 billion, strengthening its life sciences software strategy. The deal combines Arisglobal’s AI-enabled safety and regulatory intelligence with Dassault’s modeling and simulation assets, aiming to build a unified AI platform that connects real-world evidence and virtual evidence for biopharma and regulated R&D workflows.